Cara Therapeutics, Inc. announced that Frédérique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7156 USD | -5.85% | -8.04% | -3.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.69% | 39.12M | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024